Citations

Clear

9383 citation(s) found for "Thomas, PS".

Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients
Riner, Andrea N. , Rajpara, Seeta , Qian, Jing , Jin, Yuxin , Loza, Donna, Akki, Ashwin , Raj, Rohit , Merchant, Nipun B. , Hughes, Steven , Reams, Renee, Redda, Ken, Odedina, Folakemi T., Agyare, Edward , Craig, David W. , Carpten, John D. , Trevino, Jose , Velazquez‐Villarreal, Enrique , Herremans, Kelly M. , Williams, Terence M. , George, Thomas J. , Hughes, Steven J., Stern, Mariana Carla , Redda, Ken, Wilkie, Diana J. , Chamala, Srikar , Han, Bo

Mayo Clinic

Pancreas | February 25, 2025 | Volume: 54 | Issue: 3 | Pages: e171-e178

10.1097/mpa.0000000000002408 | PMID 39999309 Get It

Objectives Black/African American (B/AA) pancreatic ductal adenocarcinoma (PDAC) patients have worse clinical outcomes than White patients and are underrepresented in genomic databases. We aimed to expand our understanding of the PDAC somatic landscape from a diverse cohort. Materials and Methods Formalin-fixed paraffin-embedded specimens from 24 surgically resected PDAC cases were collected, with self-reported race/ethnicity. Whole exome sequencing was performed on malignant and benign tissue. Bioinformatics analysis included deduction of genetic ancestry and somatic mutational analysis, with comparisons to public datasets. Results Out of 24 cases, 17 identified as B/AA race; genetic ancestry analysis confirmed proportions of Sub-Saharan African ancestry greater than 47%. The most commonly mutated genes included KRAS , TP53 , SMAD4 , and CDKN2A . Comparison of mutations in our cohort versus publicly available, predominantly White datasets showed higher mutation frequencies of ATM, RREB1, BRCA1/2, KDM6A, ARID1A, BRAF, and MYC ( P < 0.04). When cohorts were combined and analyzed by race, no mutation frequencies differences were observed, including KRAS . Conclusions Genomic analysis of PDAC tumors from B/AA and White patients demonstrate similarities in mutation frequencies. Larger studies are needed to further understand molecular characterizations across continental subpopulations. This study provides further rationale for equitable representation of diverse patients in genomic databases and clinical trials.
MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients
Akkina, Sanjeev , Piper, James B., Busque, Stéphan , Mai, Martin L., Vera, Michael E. de , Collette, Suzon , Patel, Anup , Stites, Erik, Micsa, Lenuta, Brennan, Daniel C. , Kaufman, Dixon B. , Stegall, Mark D. , Asch, William Stuart , Gaber, A. Osama , Mai, Martin L., Shah, Ashesh P.

Mayo Clinic

Journal of the American Society of Nephrology | February 23, 2025 | Volume: 34 | Issue: 11S | Pages: B3-B3

10.1681/asn.20233411b3a Get It

Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic
Saunders, David , Hellwig, Lydia D. , Pagani, Austin, Castro, Mauricio De , Poon, Lucas, Ehat, Nate, Heroy, Andrew , Libbus, Joya, Fox, Keiko , Kalra, Sachi, Black, John L. , Scherer, Steven E. , Moyer, Ann M. , Black, John Logan, Haigney, Mark C. , Kalra, Sachi, Arnold, Thomas B. , Turner, Clesson

Mayo Clinic

Pharmacogenomics | February 21, 2025 | Volume: 25 | Issue: 16-18 | Pages: 637-645

10.1080/14622416.2025.2466413 | PMID 39981562 Get It

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cai, Cindy X. , Hribar, Michelle R. , Swaminathan, Swarup S. , Flowers, Alexis , Brown, Eric N. , Chen, John J. , Chen, Aiyin , Wang, Sophia Y. , Ehrlich, Joshua R. , Armbrust, Karen R. , Alshammari, Thamir , Swerdel, Joel N. , Suchard, Marc A. , Falconer, Thomas , DuVall, Scott L. , Viernes, Benjamin , O’Brien, William J. , Martin, Benjamin , Westlund, Erik , Mathioudakis, Nestoras , Fan, Ruochong, Stocking, Jacqueline C. , Takkouche, Sahar , Humes, Izabelle, McCoy, David , Adibuzzaman, Mohammad, Areaux, Raymond G. , Rojas‐Carabali, William , Brash, James T., Lee, David A. , Mawn, Louise A. , Agrawal, Rupesh, Morgan‐Cooper, Hannah, Desai, Priya , Ryan, Patrick , Barkmeier, Andrew, Chen, John J , Mathioudakis, Nestoras N , Stocking, Jacqueline C , Lee, Cecilia S , Baxter, Sally L. , Goetz, Kerry , Toy, Brian C. , Xu, Benjamin Yixing , Leng, Theodore , Barkmeier, Andrew J. , Boland, Michael V. , Dorr, David A , Boyce, Danielle M. , Schuemie, Martijn J. , Bu, Fan , Sena, Anthony G. , Hripcsak, George , Nishimura, Akihiko, Nagy, Paul G. , Matheny, Michael E. , Zhang, Linying , Martin, Benjamin, Fan, Ruochong, Wilcox, Adam B , Lai, Albert M. , Lee, Lok Hin , Xie, Yangyiran , Weiskopf, Nicole G. , Desai, Priya

Mayo Clinic

JAMA Ophthalmology | February 20, 2025 | Volume: 143 | Issue: 4 | Pages: 304

10.1001/jamaophthalmol.2024.6555 | PMID 39976940 Get It

Importance Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), has recently been implicated in cases of nonarteritic anterior ischemic optic neuropathy (NAION), raising safety concerns in the treatment of type 2 diabetes (T2D). Objective To investigate the potential association between semaglutide and NAION in the Observational Health Data Sciences and Informatics (OHDSI) network. Design, Setting, and Participants This was a retrospective study across 14 databases (6 administrative claims and 8 electronic health records). Included were adults with T2D taking semaglutide, other GLP-1RA (dulaglutide, exenatide), or non–GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from December 1, 2017, to December 31, 2023. The incidence proportion and rate of NAION were calculated. Association between semaglutide and NAION was assessed using 2 approaches: an active-comparator cohort design comparing new users of semaglutide with those taking other GLP-1RAs and non–GLP-1RA drugs, and a self-controlled case-series (SCCS) analysis to compare individuals’ risks during exposure and nonexposure periods for each drug. The cohort design used propensity score–adjusted Cox proportional hazards models to estimate hazard ratios (HRs). The SCCS used conditional Poisson regression models to estimate incidence rate ratios (IRRs). Network-wide HR and IRR estimates were generated using a random-effects meta-analysis model. Exposures GLP-1RA and non–GLP-1RAs. Main Outcomes and Measures NAION under 2 alternative definitions based on diagnosis codes: one more inclusive and sensitive, the other more restrictive and specific. Results The study included 37.1 million individuals with T2D, including 810 390 new semaglutide users. Of the 43 620 new users of semaglutide in the Optum’s deidentified Clinformatics Data Mart Database, 24 473 (56%) were aged 50 to 69 years, and 26 699 (61%) were female. The incidence rate of NAION was 14.5 per 100 000 person-years among semaglutide users. The HR for NAION among new users of semaglutide was not different compared with that of the non–GLP-1RAs using the sensitive NAION definition—empagliflozin (HR, 1.44; 95% CI, 0.78-2.68; P = .12), sitagliptin (HR, 1.30; 95% CI, 0.56-3.01; P = .27), and glipizide (HR, 1.23; 95% CI, 0.66-2.28; P = .25). The risk was higher only compared with patients taking empagliflozin (HR, 2.27; 95% CI, 1.16-4.46; P = .02) using the specific definition. SCCS analysis of semaglutide exposure showed an increased risk of NAION (meta-analysis IRR, 1.32; 95% CI, 1.14-1.54; P &amp;lt; .001). Conclusions and Relevance Results of this study suggest a modest increase in the risk of NAION among individuals with T2D associated with semaglutide use, smaller than that previously reported, and warranting further investigation into the clinical implications of this association.
Lipodystrophy Severity Score to Assess Disease Burden in Lipodystrophy
Brown, Rebecca J. , Akıncı, Barış , Yosef, Matheos , Phillips, Helen , Khalatbari, Shokoufeh , Santini, Ferruccio , Brush, Maiah, Meral, Rasimcan , Prodam, Flavia , Schnurbein, Julia von , Sorice, Gian Pio , Güler, Merve Çelik , Patni, Nivedita , Tanrıkulu, Seher , Ozgen, Basak S, Foss‐Freitas, Maria Cristina , Özışık, Seçil , Segrestin, Bérénice , Özcan, Büşra, Adıyaman, Süleyman Cem , Musolino, Gianluca , Sekizkardes, Hilal , Musso, Carla , Simha, Vinaya , Stears, Anna, Gambineri, Alessandra , Semple, Robert K. , Prodam, Flavia , von Schnurbein, Julia , Sekizkardes, Hilal , Lebenthal, Yael , Simha, Vinaya , Wabitsch, Martin , Oral, Elif A , Brown, Rebecca J. , Sorkina, Ekaterina , Vigouroux, Corinne , Ceccarini, Giovanni , Zeybel, Müjdat , Al-Yaarubi, Saif , Ozgen, Basak S, Özen, Samim , Şimşir, İlgın Yıldırım , Scherer, Thomas , Lima, Josivan Gomes , Araújo‐Vilar, David , Hegele, Robert Alexander , Oral, Elif A

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | February 19, 2025 | Volume: 110 | Issue: 11 | Pages: 3243-3255

10.1210/clinem/dgaf103 | PMID 39970125 Get It

Abstract Context Lipodystrophy syndromes are rare disorders characterized by deficient adipose tissue, leading to insulin resistance, dyslipidemia, and organ system abnormalities. Objective Our goal was to develop a lipodystrophy severity score (LDS) to holistically capture the diverse manifestations of lipodystrophy into a numerical score to aid in prediction of clinical outcomes and/or treatment impact. Design An 8-domain LDS was developed by 8 disease experts in consultation with patient organizations. The LDS was rated for feasibility and content validity by 28 additional clinicians and 9 patient representatives. LDS was compared to the Clinical Global Impression (CGI) of severity for 20 putative patient profiles, each at 2 different time points, and by comparing change in LDS to global impression of change. For external validation, LDS was calculated in 2 cohorts of patients with lipodystrophy treated with metreleptin. Results LDS domains include Diabetes/Insulin Resistance, Microvascular Complications of Diabetes, Lipids, Cardiovascular, Liver, Kidney, Reproductive, and Other. Each domain is assessed by 1 or more questions assessing both lifetime and recent complications of lipodystrophy. The LDS had high content validity and feasibility and high reliability by intraclass correlation coefficients (&gt;0.95). Global and domain-specific LDS were strongly correlated with CGI, as were changes in scores across visits (R = 0.79-0.99, P &lt; .001 for all). In generalized lipodystrophy, metreleptin significantly reduced LDS (from 46 to 26 at 12 months, P &lt; .001). The reductions were smaller in partial lipodystrophy (from 65 to 61 at 12 months, P = .04). Conclusion The LDS can reflect the severity of diverse manifestations of lipodystrophy and monitor changes following interventions.
Self-Efficacy is Associated with Health Behaviors Related to Obesity and Cardiovascular Risk among Hispanic/Latinx and Somali Immigrants to the United States
Tranby, Brianna , Clark, Matthew M. , Novotny, Paul J. , Pardo, Laura Suarez, Iteghete, Sheila, Zeratsky, Katherine, Rieck, Thomas , Molina, Luz, Capetillo, Graciela Porraz, Ahmed, Yahye, Dirie, Hana, Novotny, Paul, Lohr, Abby, Wieland, Mark, Sia, Irene G. , Lohr, Abby M. , Patten, Christi A. , Wieland, Mark L.

Mayo Clinic

No container title available | February 19, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6001516/v1 | PMID 40034444 Get It

Abstract Background: Self-efficacy theory proposes that confidence to engage in a health behavior is associated with engaging in that specific behavior. Most research examining self-efficacy has been conducted with white young adult populations. This secondary analysis examined the association of self-efficacy (i.e., confidence) for healthy eating and physical activity in two immigrant communities. Methods: At enrollment into the Healthy Immigrant Community study, a clinical weight management and cardiovascular risk reduction intervention set in southeastern [state], 475 participants completed assessments about their confidence for healthy eating and physical activity. Measurements also included self-reports of dietary quality and intake, physical activity, quality of life, and biometric assessments. Study materials were available in English, Spanish, and Somali. Results In total, 450 adults (Hispanic/Latinx = 267; Somali = 183) completed measures at baseline and were included for analysis. Their average age was 45 years (range 18–87) and 59% were female. Confidence for healthy eating was significantly associated with self-report of eating healthy snacks ( p = < 0.0001) and less consumption of high-calorie drinks ( p = 0.02) and regular soda ( p = < 0.0001). Confidence to be physically active was significantly associated with more self-reported physical activity ( p = < 0.01). Conclusions Confidence to eat healthy and be physically active appears to be associated with having a healthier diet and higher levels of physical activity. Given the large sample size and strength of the associations, it also appears that the theoretical model of self-efficacy can be effectively measured and applied within these immigrant populations. Self-efficacy theory may be useful in understanding potential mediating mechanisms when designing future interventions with immigrant communities. ClinicalTrials.gov registration: NCT05136339; April 23, 2022
Tracking the Evolution of Cutaneous Melanoma by Multiparameter Flow Sorting and Genomic Profiling
Roma, Luca , Lorber, Thomas , Rau, Sabrina, Barrett, Michael T. , Ercan, Caner , Piscuoglio, Salvatore , Glatz, Katharina , Bubendorf, Lukas , Bubendorf, Lukas , Panebianco, Federica , Ruiz, Christian Felipe

Mayo Clinic

International Journal of Molecular Sciences | February 19, 2025 | Volume: 26 | Issue: 4 | Pages: 1758

10.3390/ijms26041758 | PMID 40004220 Get It

Intratumoral heterogeneity and clonal evolution are pivotal in the progression and metastasis of melanoma. However, when combined with variable tumor cellularity, intratumoral heterogeneity limits the sensitivity and accuracy of uncovering a cancer’s clonal evolution. In this study, we combined fluorescence-activated cell sorting (FACS) with whole-exome sequencing (WES) to investigate the clonal composition and evolutionary patterns in seven melanoma biopsies obtained from three patients, each having both primary site and metastatic samples. We employed a multiparameter ploidy sorting approach to isolate tumor populations based on DNA ploidy and melanoma biomarkers (SOX10 or S100), enabling us to investigate clonal evolution with high resolution. Our approach increased the mean tumor purity from 70% (range 19–88%) in unsorted material to 91% (range 87–96%) post-sorting. Our findings revealed significant inter- and intratumor heterogeneity, with one patient exhibiting two genomically distinct clonal tumor populations within a single primary site biopsy, each giving rise to different metastases. Our findings highlight the critical role of intratumoral heterogeneity and clonal evolution in melanoma, especially when analyzing tumor trajectories. The unique combination of multiparameter FACS and WES provides a powerful method for identifying clonal populations and reconstructing clonal evolution. This study provides valuable insights into the clonal architecture of melanoma and lays the groundwork for future research with larger patient groups.
Dissociable spatial topography of cortical atrophy in early‐onset and late‐onset Alzheimer's disease: A head‐to‐head comparison of the LEADS and ADNI cohorts
Katsumi, Yuta , Touroutoglou, Alexandra , Brickhouse, Michael , Eloyan, Ani , Eckbo, Ryan, Zaitsev, Alexander, Joie, Renaud La , Thangarajah, Maryanne, Taurone, Alexander, Jack, Clifford R. , Dage, Jeffrey L. , Hammers, Dustin B. , Newell, Kathy L. , Polsinelli, Angelina J. , Aisen, Paul, Reman, Rema, Kramer, Joel H. , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Grant, Ian , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Turner, Raymond Scott , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Jack, Clifford R , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Lagarde, Julien , Schonhaut, Daniel R. , Vemuri, Prashanthi , Nudelman, Kelly , Foroud, Tatiana , Hammers, Dustin B , Ghetti, Bernardino , Murray, Melissa E. , Beckett, Laurel , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Wolk, David A. , Womack, Kyle , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | February 19, 2025 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14489 | PMID 39968692 Get It

Abstract INTRODUCTION Early‐onset and late‐onset Alzheimer's disease (EOAD and LOAD, respectively) have distinct clinical manifestations, with prior work based on small samples suggesting unique patterns of neurodegeneration. The current study performed a head‐to‐head comparison of cortical atrophy in EOAD and LOAD, using two large and well‐characterized cohorts (LEADS and ADNI). METHODS We analyzed brain structural magnetic resonance imaging (MRI) data acquired from 377 sporadic EOAD patients and 317 sporadicLOAD patients who were amyloid positive and had mild cognitive impairment (MCI) or mild dementia (i.e., early‐stage AD), along with cognitively unimpaired participants. RESULTS After controlling for the level of cognitive impairment, we found a double dissociation between AD clinical phenotype and localization/magnitude of atrophy, characterized by predominant neocortical involvement in EOAD and more focal anterior medial temporal involvement in LOAD. DISCUSSION Our findings point to the clinical utility of MRI‐based biomarkers of atrophy in differentiating between EOAD and LOAD, which may be useful for diagnosis, prognostication, and treatment. Highlights Early‐onset Alzheimer's disease (EOAD) and late‐onset AD (LOAD) patients showed distinct and overlapping cortical atrophy patterns. EOAD patients showed prominent atrophy in widespread neocortical regions. LOAD patients showed prominent atrophy in the anterior medial temporal lobe. Regional atrophy was correlated with the severity of global cognitive impairment. Results were comparable when the sample was stratified for mild cognitive impairment (MCI) and dementia.
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Pal, Sumanta K. , Loriot, Yohann , Necchi, Andrea , Singh, Parminder , Castellano, Daniel , Pagliaro, Lance C. , Suárez, Cristina , McGregor, Bradley A. , Vaishampayan, Ulka N. , Hauke, Ralph J. , Herpen, Carla M.L. van , Sudhagoni, Ramu, Schwickart, Martin, Andrianova, Svetlana, Powles, Thomas , Van Herpen, Carla M L , Courtney, Kevin D , Dreicer, Robert , Agarwal, Archana M , Necchi, Andrea , McGregor, Bradley , Vaishampayan, Ulka , Loriot, Yohann , Singh, Parminder , Dreicer, Robert , Agarwal, Neeraj

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 14 | Pages: 1650-1662

10.1200/jco-24-01675 | PMID 39965176 Get It

PURPOSE The COSMIC-021 study assessed the safety and efficacy of cabozantinib plus atezolizumab in advanced solid tumors. Presented here are results from the expansion cohorts with advanced urothelial carcinoma (UC). METHODS This phase Ib study (ClinicalTrials.gov identifier: NCT03170960 ) enrolled patients with inoperable locally advanced/metastatic UC into four tumor cohorts: first-line cisplatin-eligible (cis-eligible), first-line cisplatin-ineligible (cis-ineligible), previous platinum-containing chemotherapy (previous chemotherapy-treated), and previous immune checkpoint inhibitor (ICI)–treated. Patients received oral cabozantinib 40 mg once daily and intravenous atezolizumab 1,200 mg once every 3 weeks. The primary end point was objective response rate (ORR), as assessed by the investigator per RECIST v1.1 every 6 weeks for 12 months and every 12 weeks thereafter; the secondary end point was safety. RESULTS A total of 121 patients (previous ICI-treated cohort, n = 31, and each of the other cohorts, n = 30) received study treatment from March 2018 to November 2021. The ORR (95% CI) was 30% (15 to 49) for cis-eligible, 20% (8 to 39) for cis-ineligible, 27% (12 to 46) for previous chemotherapy-treated, and 10% (2 to 26) for previous ICI-treated cohorts. The median progression-free survival (95% CI) was 5.5 (1.6 to 11.6), 5.6 (3.1 to 11.1), 5.4 (1.6 to 7.6), and 3.0 (1.8 to 5.5) months, respectively. Grade 3 or 4 treatment-related adverse events (TRAEs) were experienced by 43%, 67%, 57%, and 45% of patients, respectively. TRAEs led to discontinuation of all treatment components in 17%, 13%, 3%, and 19%, respectively. No grade 5 TRAEs were reported in any cohort. CONCLUSION The novel combination of cabozantinib plus atezolizumab exhibited clinical activity in advanced UC that is cis-eligible, cis-ineligible, or previously treated with platinum-containing chemotherapy; clinical activity in previous ICI-treated UC was modest. The toxicity profile was consistent with that previously reported for the combination.
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Hansen, Doris K. , Peres, Lauren C. , Dima, Danai , Richards, Alicia, Shune, Leyla , Afrough, Aimaz , Midha, Shonali , Dhakal, Binod , Kocoglu, Mehmet H. , Atrash, Shebli , Ferreri, Christopher, Davis, James A. , Bhurtel, Jenny , Wagner, Charlotte B , Bansal, Radhika , Smith, Kinaya, Avila, Gabriel De, Purvey, Sneha , Hosoya, Hitomi , Mikkilineni, Lekha , Oswald, Laura B. , Gaballa, Mahmoud , Forsberg, Peter A. , Janakiram, Murali , Htut, Myo , Maringanti, Sireesha Asoori, Kalariya, Nilesh, Hashmi, Hamza , Sborov, Douglas W. , Khouri, Jack , Raza, Shahzad , Atanackovic, Djordje , Alsina, Melissa , Freeman, Ciara Louise , Voorhees, Peter M. , Anderson, Larry D. , Martin, Thomas, Patel, Krina K. , Sidana, Surbhi , Castaneda Puglianini, Omar , Davis, James A , Bhurtel, Evguenia , McGuirk, Joseph , Wagner, Charlotte , Bansal, Radhika , Lieberman-Cribbin, Alex , De Avila, Gabriel , Purvey, Sneha , Hosoya, Hitomi , Kaur, Gurbakhash , Herr, Megan M. , Janakiram, Murali , Reshef, Ran , Sborov, Douglas W , Anwer, Faiz , Khouri, Jack , Alsina, Melissa , Locke, Frederick L , Voorhees, Peter , Anderson, Larry D , Lin, Yi , Patel, Krina , Sidana, Surbhi , Dima, Danai , Kocoglu, Mehmet H , Raza, Shahzad , Atrash, Shebli , Hansen, Doris K , Dhakal, Binod , Puglianini, Omar Castañeda , McGuirk, Joseph P. , Costello, Patrick , Kaur, Gurbakhash , Pasvolsky, Oren , Reshef, Ran , Nadeem, Omar , Anwer, Faiz , Locke, Frederick L. , Richard, Shambavi , Lin, Yi

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 13 | Pages: 1597-1609

10.1200/jco-24-01730 | PMID 39965175 Get It

PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, and survival among patients with RRMM treated with standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of patients with RRMM leukapheresed by December 31, 2022, with the intent to receive SOC ide-cel or cilta-cel at 19 institutions. An inverse probability of treatment weighting (IPTW) approach was used to compare outcomes by therapy type. RESULTS A total of 641 patients were leukapheresed by December 31, 2022, with ide-cel (n = 386) and cilta-cel (n = 255). Five hundred eighty-six patients were infused (n = 350 for ide-cel; n = 236 for cilta-cel) with a median follow-up of 12.6 and 13.0 months for ide-cel and cilta-cel, respectively. After IPTW, patient characteristics were well balanced. Cilta-cel was associated with higher likelihood of grade ≥3 cytokine release syndrome (CRS; odds ratio [OR], 6.80 [95% CI, 2.28 to 20.33]), infections (OR, 2.03 [95% CI, 1.41 to 2.92]), second primary malignancies (OR, 1.77 [95% CI, 0.89 to 3.56]), and delayed neurotoxicity (OR, 20.07 [95% CI, 4.46 to 90.20]). Cilta-cel was also associated with better treatment responses (≥complete response: OR, 2.42 [95% CI, 1.63 to 3.60]), longer progression-free survival (hazard ratio [HR], 0.48 [95% CI, 0.36 to 0.63]), and longer overall survival (HR, 0.67 [95% CI, 0.46 to 0.97]). No associations were observed between therapy type and immune effector cell–associated neurotoxicity syndrome, any CRS, severe cytopenia at days 30 and 90, or nonrelapse mortality. We observed consistent findings when repeating the analyses restricting the ide-cel cohort to patients infused during the same time period as Food and Drug Administration approval for cilta-cel (≥March 2022). CONCLUSION Cilta-cel demonstrated superior efficacy and survival, with higher incidence of certain toxicities, compared with ide-cel.